T Cells: The Future Roadmap of The USD 15 Billion+ Opportunity

Although cancer therapeutics continue to be one of the most active areas in terms of drug development, there is still a significant unmet need in this domain. Conventional cancer treatments, such as chemotherapy, surgery and radiation therapy, have demonstrated very limited efficacy in late-stage cancers. Amidst the current initiatives to develop more targeted anti-cancer therapies, T cell therapy has emerged as a potent and viable therapeutic intervention to eradicate tumour cells, with minimal side effects. It is based on the principle of harnessing the innate potential of the immune system to target and destroy diseased cells. There are certain key characteristics that render CAR-T cells suitable for use as effective therapeutic tools; these include target specificity, adaptability and the capability to retain immunologic memory.

With 2 approved therapies and over 365 clinical / preclinical product candidates, the CAR-T cells therapies pipeline has evolved significantly over the last few years

As per Roots Analysis, currently CAR-T therapies pipeline includes over 365 therapies that are marketed or in clinical stage

More than 100 industry players are involved in developing T cell therapy; academic institutes continue to make significant contributions to the innovation in this field

Around 35% of the CAR-T therapies are currently in discovery stage. Additionally, close to 50% of therapies are used for hematological cancer

The discovery of novel, disease-specific targets has opened up new avenues for the development of CAR-T based treatment options for a diverse range of cancer indications.

A number of prominent scientists have emerged as key opinion leaders in this domain, having led / presently leading various CAR-T therapy related clinical development efforts.

Over time, multiple generations of CAR constructs based on a variety of scFv fragments using different vector types, have been developed to improve therapeutic efficiency.

The adoption of marketed therapies indicates that this credible promise can be turned into reality by deploying diverse promotional strategies.

The growing optimism is also evident in the opinions expressed by several industry / academic stakeholders and on social media.

With a robust development pipeline and encouraging clinical outcomes, the CAR T cell therapy market is anticipated to grow at an annualized rate of over 50% and be worth USD 15 billion by 2030

The CAR-T therapies market is fragmented across different segments. Further, it is worth mentioning that market is likely to grow at a CAGR of 50%.

You can also download the SAMPLE REPORT on CAR T cells therapy by Roots Analysis. 

Our Social Media Platform

Web: https://www.rootsanalysis.com/

LinkedIn: https://in.linkedin.com/company/roots-analysis

Twitter: https://twitter.com/RootsAnalysis.com